SCHEMBL21858342

SCHEMBL21858342

COc1cc(Cl)ccc1NC(=O)c1cc(=O)c2cc(Cl)cc(Cl)c2o1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.62
GPR35 Q9HC97 11/20 0.53
THRB P10828 1/20 0.52
CSNK2A2 P19784 2/20 0.49
CSNK2B P67870 2/20 0.49
CSNK2A1 P68400 2/20 0.49
MAPT P10636 1/20 0.48
KMT2A Q03164 2/20 0.47
DUSP3 P51452 1/20 0.47
PTPN11 Q06124 1/20 0.47
TSHR P16473 3/20 0.45
HSD17B10 Q99714 3/20 0.45
KDM4E B2RXH2 2/20 0.45
GPR55 Q9Y2T6 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21858217 0.88 TP53 (0.58) TP53GPR35THRBMAPTKMT2A
SCHEMBL21858264 0.85 MAPT (0.52) TP53GPR35THRBMAPTKMT2A
SCHEMBL21858267 0.85 TP53 (0.57) TP53GPR35MAPTKDM4EALDH1A1
SCHEMBL21858222 0.84 GPR35 (0.51) TP53GPR35THRBMAPT
SCHEMBL21858228 0.83 TP53 (0.46) TP53GPR35THRBMAPTTSHR
SCHEMBL21858216 0.81 TP53 (0.45) TP53GPR35THRBTSHR
SCHEMBL21858284 0.81 TP53 (0.47) TP53GPR35THRBMAPTKMT2A
SCHEMBL21858215 0.74 TP53 (0.50) TP53GPR35THRBKMT2ADUSP3
SCHEMBL19743718 0.74 GPR35 (0.49) TP53GPR35THRBCSNK2A2CSNK2B
SCHEMBL21858315 0.73 RAB9A (0.56) TP53GPR35THRBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993591-B2 Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2024-05-28 US disclosed
US-20220402897-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2022-12-22 US disclosed
US-20220402897-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2022-12-22 US disclosed
CN-112839714-A Chromen-4-one derivatives for the treatment and prevention of hepatitis B virus diseases 豪夫迈·罗氏有限公司 2021-05-25 CN disclosed
WO-2020079106-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-04-23 WO disclosed
WO-2020079106-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993591-B2 Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease HAVCR2, CYP7A1, CYP26B1 TP53 276/4885GPR35 3566/4885THRB 301/4885
US-20220402897-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HAVCR2, CYP7A1, CYP26B1 TP53 276/4885GPR35 3566/4885THRB 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.